XERSXERSHealthcare · Drug Manufacturers - Specialty & Generic

XERS Stock Forecast: Xeris Biopharma Holdings, Inc. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$17
+1.13% on the day

The 7 Wall Street analysts covering Xeris Biopharma Holdings, Inc. hold a median 12-month price target of $18 — +5.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 100 of 100 as at 17 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$3.1B
Ticker Nerd rank
100/ 100
Median analyst target
$18
Analysts covering
7
Revenue$92.1M+28.7% y/y
Operating income$5.2M
Net income−$31.1M
Free cash flow$8.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.8%
1M
+64.8%
YTD
+116.4%
1Y
+140.0%
From 52W high
0.0%
From 52W low
+221.2%
$5
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XERS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xeris Biopharma Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
100/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
98
Value
96
Momentum
94
Revisions
90
Accruals
87
Volatility
83
Issuance
71
Growth
65
Size
29

Quality (98): The business earns solid, repeatable profits on what it owns.

Growth (65): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (29): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XERS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XERS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26XERSHigh $21Median $18Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $12Median $18High $21

The green dot is the last close — the median target sits +5.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Nov 2026BarclaysMaintainsOverweight$14 → $18
6 Nov 2026HC Wainwright & Co.MaintainsBuy$10 → $18
6 Nov 2026OppenheimerReiteratesOutperform$18 → $21
6 Nov 2026Piper SandlerReiteratesNeutral$8.00 → $12
6 Oct 2026BarclaysMaintainsOverweight—
6 Oct 2026BarclaysMaintainsOverweight$12 → $14
10 Sept 2026Leerink PartnersMaintainsOutperform$12 → $16
10 Sept 2026Leerink PartnersMaintainsOutperform—
20 Aug 2026BarclaysMaintainsOverweight—
20 Aug 2026BarclaysMaintainsOverweight$9.00 → $12
2 Mar 2026HC Wainwright & Co.ReiteratesBuy$10
2 Mar 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
9 Dec 2025BarclaysInitiatesOverweight—
7 Nov 2025HC Wainwright & Co.MaintainsBuy—
7 Nov 2025OppenheimerMaintainsOutperform—
7 Nov 2025Piper SandlerMaintainsNeutral—
29 Oct 2025OppenheimerMaintainsOutperform—
17 Sept 2025HC Wainwright & Co.MaintainsBuy—
19 Aug 2025Leerink PartnersMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

XERS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XERS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Xeris Biopharma Holdings, Inc. returned +140.0% against +12.2% for the S&P 500, dividends included.

XERS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26XERSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XERS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Xeris Biopharma Holdings, Inc. (XERS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
117.6×

Cheaper than 6% of US stocks

Price / sales
8.3×

Cheaper than 15% of US stocks

Price / book
62.9×

Cheaper than 2% of US stocks

EV / EBITDA
53.4×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
44.2%

Higher than 84% of US stocks

Earnings growth (YoY)
1718.0%

Higher than 98% of US stocks

Gross margin
86.4%

Higher than 95% of US stocks

Operating margin
12.7%

Higher than 70% of US stocks

Net margin
−1.8%

Higher than 27% of US stocks

Returns & dividend
Return on equity
−27.1%

Higher than 28% of US stocks

Return on assets
7.4%

Higher than 86% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Xeris Biopharma Holdings, Inc. (XERS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xeris Biopharma Holdings, Inc. has a market value of $3.1B and an enterprise value of $3.1B.

  • Revenue in the twelve months to 30 June 2026: $335.4M. The latest quarter grew 44.2% year on year.

  • Net income over the same four quarters: −$17.2M, a −5.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.11.

  • Free cash flow in the twelve months to 30 June 2026: $55.7M, after $938K of capital spending.

  • Xeris Biopharma Holdings, Inc. spent $19.2M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 173.6M.

  • Trailing P/E: 117.6×; forward P/E: 63.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Xeris Biopharma Holdings, Inc. employs 435 people — $771K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 17 Nov 2026

Data provided by Twelve Data

Peers

XERS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
XERSXeris Biopharma Holdings, Inc.$3.1B100
AMLXAmylyx Pharmaceuticals, Inc.$3.5B60
SUPNSupernus Pharmaceuticals, Inc.$2.4B—
PBHPrestige Consumer Healthcare, Inc.$2.3B57
HIMSHims & Hers Health, Inc.$4.1B12
RGCRegencell Bioscience Holdings Ltd.$2.3B22
PRGOPerrigo Co. Plc$2.2B90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xeris Biopharma Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XERS news & analysis

Xeris Biopharma: Time For A Pause

Seeking Alpha · 12 Nov 2026positive

The Seeking Alpha article reports that Xeris Biopharma shares more than doubled since the author’s March buy rating, following strong Q3 results and raised guidance. XERS reported GAAP earnings of $0.06 per share, $11.3 million in net income, 44% revenue growth to $107.2 million, 88% gross margins, and repayment of $34 million in convertible notes.

Why it matters — These reported results, higher guidance, and reduced debt and interest costs are relevant indicators of Xeris’s recent operating performance and balance-sheet position.

Xeris Biopharma Q3 Earnings Call Highlights

MarketBeat · 6 Nov 2026positive

Xeris Biopharma raised its 2026 revenue guidance and 2030 outlook after third-quarter sales grew 44% year over year. The company attributed the increase to rapid growth in Recorlev, its Cushing syndrome treatment.

Why it matters — The updated outlook and sales growth driven by Recorlev are relevant to investors tracking Xeris’s business performance.

Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript

Seeking Alpha · 6 Nov 2026neutral

Seeking Alpha published a transcript of Xeris Biopharma Holdings’ Q3 2026 earnings call, held November 5, 2026. The excerpt identifies company executives and participating analysts but provides no discussion of results or outlook.

Why it matters — XERS watchers can note the availability of the earnings-call transcript, though the excerpt contains no substantive company updates.

Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue Estimates

Zacks Investment Research · 5 Nov 2026positive

Xeris Biopharma reported quarterly earnings of $0.06 per share, above the Zacks Consensus Estimate of $0.02. That compares with break-even earnings per share a year earlier.

Why it matters — XERS watchers may note the company exceeded the consensus earnings estimate for the quarter.

Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research · 5 Nov 2026neutral

The Zacks item says Xeris Biopharma’s Q3 revenue and EPS offer a view of its performance for the quarter ended September 2026, and focuses on how key metrics compare with Wall Street estimates and year-ago figures. The excerpt does not provide the metrics or comparisons.

Why it matters — XERS watchers may use the reported metric comparisons to assess quarterly performance against expectations and the prior year.

FAQ

Frequently asked questions about XERS stock

What is the XERS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Xeris Biopharma Holdings, Inc. have a median 12-month price target of $18, with estimates ranging from $12 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XERS stock a buy right now?

Of the 7 analysts covering Xeris Biopharma Holdings, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xeris Biopharma Holdings, Inc. 100 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XERS?

As at 17 Nov 2026, Xeris Biopharma Holdings, Inc. ranks 100 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (98 of 100).

Will XERS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +5.9% from the last close, and Ticker Nerd's factor model ranks Xeris Biopharma Holdings, Inc. 100 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XERS stock forecast for 2030?

No analyst covering Xeris Biopharma Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XERS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $21 over the next 12 months.

How has XERS stock performed over the past year?

Xeris Biopharma Holdings, Inc. returned +140.0% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xeris Biopharma Holdings, Inc. do?

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases.

What is the latest news on XERS?

The most recent item we track (Seeking Alpha, 12 Nov 2026): "Xeris Biopharma: Time For A Pause". The Seeking Alpha article reports that Xeris Biopharma shares more than doubled since the author’s March buy rating, following strong Q3 results and raised guidance. XERS reported GAAP earnings of $0.06 per share, $11.3 million in net income, 44% revenue growth to $107.2 million, 88% gross margins, and repayment of $34 million in convertible notes.

Company

About Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases. Xeris Biopharma Holdings, Inc. markets Gvoke, a ready-to-use liquid glucagon for severe hypoglycemia; Keveyis, a treatment for primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for endogenous hypercortisolemia associated with Cushing’s syndrome. The company also works with proprietary formulation technologies designed to support liquid-stable, ready-to-use injectable medicines and reduce preparation steps for patients and caregivers. Its business is centered on specialty pharmaceuticals that address complex, often long-term conditions in endocrinology, neurology, and related areas, with a focus on patient-friendly delivery formats and commercial therapies already in market.

CEO Mr. John P. Shannon · 435 employees · United States · https://www.xerispharma.com